Shuaibing Jiang and Jianyu Li's group at McGill and Mass General Brigham published the click-clotting paper in Nature on April 29: cytogels that crosslink red blood cells via a bioorthogonal "click" reaction form a solid gel in five seconds. [1] The engineered blood clots show a 13-fold increase in fracture toughness and a 4-fold improvement in adhesion energy compared with native clots. Yesterday's paper carried the clinic-pipeline read on the seconds-scale clot formation framed against North Carolina State's parallel synthetic-platelet pig liver trial. Today the McGill prep-time arithmetic is the news.

Autologous clots — built from a patient's own blood — prepare in approximately 20 minutes. Allogeneic clots from type-matched donor blood prepare in approximately 10 minutes. [2] The crosslinking chemistry doesn't interfere with native coagulation; the cytogel embeds in the body's own fibrin clot. The McGill press release records Li's framing directly: red blood cells become a structural element rather than a passive payload. In rodent liver-laceration testing, the cytogel exceeded the clinically used comparator on healing and regeneration. Minimal immune reactivity. No toxicity in major organs.

The translational profile is unusual. Endovascular embolization — the precursor McGill thesis work used the same cytogel chemistry as a temporary embolic agent — has rat and porcine in-vivo data showing controlled occlusion and seven-day enzymatic degradation. [3] The mechanical property gap (13x toughness) is large enough to potentially exceed clinical comparators in animal models already. Brown's NCSU group is targeting next-generation work on platelet-immune-cell signaling for the synthetic platelet platform; McGill's cytogel platform is targeting translation of the existing structural result. The biomaterials field has spent two decades trying to put red blood cells into structural materials. The click reaction is what made it work. The next paper to land will be the FDA pre-IND filing or the equivalent at Health Canada — the regulatory gate, not the bench.

-- KENJI NAKAMURA, Tokyo